KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly
associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is …

Simple Summary Since the Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated
in about 25% of all human cancers and is at the center of pathways involved in …

Members of the family of RAS proto-oncogenes, discovered just over 40 years ago, were
among the first cancer-initiating genes to be discovered. Of the three RAS family members …

Mutational activation of KRAS promotes the initiation and progression of cancers, especially
in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific …

KRAS is the most frequently mutated oncogene, harboring mutations in approximately one
in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment …

KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles
varies between cancers from different sites, but it is unclear whether allelic selection results …

Mutations in RAS proteins occur widely in human cancer. Prompted by the confirmation of
KRAS mutation as a predictive biomarker of response to epidermal growth factor receptor …

Simple Summary KRAS is one of the oncogenic proteins and best well-known GTPase
proteins. Although KRAS serves as regulation of cellular process, abnormal mutated and …

Background Mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)
play a critical role in cancer cell growth and resistance to therapy. Most mutations occur at …

Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known
genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of …